A pan-cancer analysis of the prognostic and immunological roles of matrix metalloprotease-1 (MMP1) in human tumors

Article type: Research Article

Keywords: MMP1, pan-cancer, prognosis, immune infiltration, molecular biology experiments

Authors: Shuai Mao, Anliang Xia, Xuewen Tao, Dingde Ye, Jiamu Qu, Meiling Sun, Haowei Wei, Guoqiang Li

Affiliations: Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Medical School, Nanjing University, Nanjing, China; Department of Hepatobiliary Surgery, Medicine School of Southeast University Nanjing Drum Tower Hospital, Nanjing, China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China

License: Copyright © 2023 Mao, Xia, Tao, Ye, Qu, Sun, Wei and Li CC BY 4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Article links: DOI: 10.3389/fonc.2022.1089550  |  PubMed: 36727076  |  PMC: PMC9885257

Relevance: Moderate: mentioned 3+ times in text

Full text: PDF (1.3 MB)

Introduction

Recently, the incidence of cancer has been increasing worldwide (ref. 1), and cancer, as the main cause of death, has become increasingly prominent. China has become a veritable cancer country (ref. 2). As a populous country in the world, cancer data from China are not optimistic, and China ranks first in the world in terms of both new numbers and deaths. Therefore, it is urgent to find tumor biomarkers and targets to conquer cancer. For any possible tumor-associated gene, it is important to explore its clinical prognostic relevance and molecular pathogenic mechanisms, let alone its pan-cancer expression. The TCGA (The Cancer Genome Atlas) and GEO (Gene Expression Omnibus) databases provide functional genomics information for different cancers (T1), which allows us to carry out pan-cancer analysis on any gene of interest (ref. 3–ref. 5).

Matrix metalloproteinase-1 (MMP1) is a Zn²⁺-dependent endopeptidase that is secreted into the extracellular matrix and specifically degrades type I, II, and III collagen fibers (ref. 6). In malignant tumors, proliferation of tumor cells is usually accompanied by high expression of MMP1 and MMP1 is activated to degrade the extracellular matrix and attenuate hindrance during cell movement, which in turn promotes tumor invasion and metastasis (ref. 7, ref. 8). Although stromal cells in the tumor microenvironment, such as cancer-associated fibroblasts, also degrade and remodel the stroma, these stromal cells also need to be activated through signal transduction pathways. MMP1 can modulate these cellular behaviors by activating receptor signal transduction pathways (ref. 9). Lu et al. found that MMP1 coordinates paracrine signaling cascades to regulate the bone microenvironment and facilitate osteoclastogenesis and bone metastasis (ref. 10). Juncker-Jensen et al. showed that a tumor MMP-1/endothelial PAR1 axis promotes intravasation and vascular dissemination (ref. 11). MMP1 is also involved in G protein signal transduction, regulating tumor angiogenesis, and promoting tumor cell resistance (ref. 12, ref. 13). Mechanistic studies of MMP1 in several tumors, including BRCA, CESC and COAD, have already been reported (ref. 10, ref. 14, ref. 15).

However, systematic pan-cancer analysis based on big data on the correlation between MMP1 expression and clinical manifestations of various tumors has not been explored. Here, we analyzed the correlation between MMP1 and clinical manifestations of different cancers from the aspects of differential gene expression, survival prognosis of cancer patients, gene mutation and tumorigenesis correlation, immune infiltration correlation, and gene-related cellular pathways. Also, we explored its potential mechanism of action in tumors and its possibility as a clinical molecular indicator of tumors (ref. 16). At last, we proved the MMP1 expression and cancer-promoting function in pancreatic cancer using biological experiments. Therefore, this study reveals the MMP1 expression and prognosis in human cancer, the relationship between MMP1 expression and tumor immunity, and the cancer-promoting effect of MMP1 in pancreatic cancer.

Materials and methods

MMP1 mRNA expression analysis

We utilized Tumor Immune Estimation Resource version 2 (TIMER2) to analyze MMP1 expression levels between tumors and paired normal tissues. In tumor types with no or limited normal tissues, we investigated MMP1 expression by using ‘Gene Expression Profile’ section of Gene Expression Profiling Interactive Analysis (version 2) (GEPIA2) to combine data from normal tissues in the Genotype-Tissue Expression (GTEx) database, under parameters of log₂FC (fold change) cutoff = 1 and P-value cutoff = 0.01. We also used ‘Pathological Stage Plot’ section to obtain MMP1 expression in TCGA cancers at each pathological stage.

MMP1 protein expression analysis and immunohistochemistry staining

UALCAN tool was utilized to perform protein expression analysis. Protein expression data were from Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset. Besides, we downloaded and analyzed immunohistochemical images of MMP1 protein expression in human pancreatic normal tissues and tumor tissues from the Human Protein Atlas (HPA).

Survival prognosis analysis and ROC curve analysis

We obtained overall survival (OS) and disease-free survival (DFS) significance maps and Kaplan–Meier (K-M) survival plots of MMP1 by utilized ‘Survival Analysis’ section of GEPIA2. We used cut-off value of 50% to split the high and low expression cohorts. Log-rank test was used to perform hypothesis testing.

We obtained RNA-seq data in transcripts per million reads (TPM) format from TCGA and GTEx uniformly processed by the Toil process (ref. 17) in UCSC XENA. Tumor data from TCGA and corresponding normal tissue data from GTEx were extracted. Expression comparisons between samples were performed after log2 transformation of RNA-seq data in TPM format. Finally, we utilized R package pROC (version 1.17.0.1) to analyze data and R package ggplot2 (version: 3.3.3) to visualize the results.

Genetic alteration analysis

The cBioPortal tool was employed to analyze MMP1 genetic alterations. Alteration frequency and type and mutated site for MMP1 from TCGA Pan-Cancer Atlas Studies were obtained and analyzed. We input ‘MMP1’ to ‘Quick Search’ module, and genetic alterations and mutated site data can be obtained from ‘Cancer Types Summary’ and ‘Mutations’ modules.

According to whether MMP1 was mutated or not, we divided the limited tumor sample data available from the TCGA into MMP1 altered and unaltered groups and compared their prognoses, including OS, disease-specific survival (DSS) and progress-free survival (PFS).

Immune infiltration analysis

MCPCOUNTER, TIDE and EPIC algorithms were employed to investigate the correlation between MMP1 expression and infiltration of CAFs in the ‘Immune Association’ section of TIMER2.

We obtained the tumor dataset from the UCSC database. Immediately, the MMP1 expression data in each sample were extracted. Then, we chose samples from which the samples were derived from Primary Blood Derived Cancer-Peripheral Blood, Primary Tumor Correlation test and Metastatic samples of TCGA-SKCM. Besides, tumor gene expression profiles were extracted. Subsequently, we mapped them to GeneSymbol. Finally, R package ESTIMATE (version 1.0.13) was used to calculate stromal, immune, and estimate scores, and the corr. test function of R package psych (version 2.1.6) was utilized to calculate Pearson’s correlation between MMP1 expression and immune infiltration scores.

Correlation analysis of MMP1 expression with TMB and MSI

We obtained tumor data from UCSC, and MMP1 expression data were extracted. Then we chose samples from which the samples were derived from Primary Blood Derived Cancer-Peripheral Blood and Primary Tumor. We also obtained the Simple Nucleotide Variation dataset of level4 for TCGA samples from GDC treated by MuTect2 software. TMB score were calculated by using maftools R package (version 2.8.05). Besides, we obtained MSI score from a previous study (ref. 18). Finally, we explored Spearman’s correlations between TMB and MSI and MMP1 expression.

Protein network and MMP1-related gene enrichment analysis

GeneMANIA website was utilized to find functionally similar genes using a large body of genomics and proteomics data, and we used it to search for genes that are functionally similar to MMP1. Also, a human MMP1-binding protein co-expression network can be obtained by STRING tool. Next, we set the main parameters: max number of interactors to show (‘no more than 20 interactors’), minimum required interaction score [‘highest confidence (0.700)’], active interaction sources (select all), meaning of network edges(‘evidence’), and Network type (‘full STRING network’). All gene symbols were used as input gene symbols for Gene Ontology pathway enrichment analysis with R package clusterProfiler (version: 3.14.3). In the end, we utilized R package ggplot2 (version: 3.3.3) to visualize the results.

Cell culture and transfection

Human PAAD cell lines (AsPC-1, PANC-1 and SW1990) were purchased from Shanghai Institute of Biochemistry and Cell Biology. Cells were passaged and cryopreserved by the Central Laboratory of Hepatobiliary Pancreas, Nanjing Drum Tower Hospital. Human normal pancreatic cell line (HPDE) and PAAD cell lines (Capan-2 and BxPC-3) were derived from our laboratory. Cells were cultured in DMEM (Dulbecco’s modified Eagle’s medium) or RPMI 1640 containing 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin (WISENT, China). All cells were cultured at 37°C with 5% CO2. Moreover, all siRNAs (si-NC, si-MMP1) that purchased from RiboBio (Guangzhou, China) were transfected into BxPC-3 and Capan-2 cells by using Lipofectamine 3000 (Invitrogen, USA). At 2 days after transfection, cells were collected for following experiments. The sequences of siRNAs were displayed in Supplementary Table 1.

Western blotting analysis

RIPA buffer (Beyotime, China) was used to lyse cells to extract total protein. The treated protein samples were then subjected to SDS-PAGE. We transferred the separated protein onto PVDF membranes after electrophoresis. Membranes were blocked with blocking solution (5% skim milk) and then primary antibodies (MMP1, Abcam; GAPDH, Abcam) were used to incubate membranes overnight. After incubation with secondary antibodies, proteins were visualized with high-sensitivity electrochemiluminescence agent (Beyotime, China) followed by autoradiography.

Wound healing assay

Culture-Inserts 2 Well for self-insertion (Ibidi, Germany) were placed into wells of 6-well plates. Cells were digested with trypsin, and resuspended with DMEM medium containing 1% FBS and 1% penicillin–streptomycin. 3×10⁴ cells were seeded in each well of the insert. After one night, the insert was removed. Cell migration was observed by photography in an Olympus CKX41 inverted microscope at 0 and 48 h. The scratch area at 0 and 48 h was measured using Image J software.

Transwell assay

Transwell inserts (Corning, USA) were coated with Matrigel (BD biosciences, USA). 1 × 10⁵ cells were seeded in the upper chamber with serum-free DMEM, and serum containing DMEM was added to the lower chamber. Cells were incubated in 37°C incubator for 24h. Then, cells attached to the chamber were fixed in 4% paraformaldehyde. After 20 minutes, the chamber was moved into 0.1% crystal violet. Finally, cells in the upper chamber and Matrigel were gently removed with cotton swabs, and the total number of invaded cells was counted under an Olympus IX73 inverted microscope.

CCK8 detection

PAAD cells transfected with si-MMP1 and si-NC in logarithmic growth phase were seed in 96-well plates at 1000 cells/well density, and 5 multiple wells were designed for each group. After incubation for 24h 48h and 72h, a volume of 10 μL CCK8 solution (Vazyme, China) was added to each well and incubated in an incubator for 1 h. The wavelength at OD450 was measured in a multiplate reader.

Flow cytometry assay

According to manufacturer’s instructions, samples were stained with Annexin V-FITC and propidium iodide (Vazyme, China). Then, an Aria flow cytometer (BD Biosciences, USA) was utilized to display the apoptotic cell population. Finally, FlowJo software was used to analyze data.

Statistical analysis

Data were analyzed using GraphPad Prism, version 6.00 and SPSS, version 20.0. We employed One-way ANOVA to compare multiple groups, and Student’s t-test to compare two groups. Data were reported as means ± SD. P ≤ 0.05 was considered statistically significant.

Results

Expression analysis of MMP1

TIMER2 was utilized to investigate MMP1 expression levels between tumor tissues and control tissues from the TCGA database. MMP1 expression levels were significantly higher in 19 tumor types than in corresponding controls. Notably, the mRNA levels of MMP1 were only lower in KICH than in control tissues. In addition, MMP1 expression levels were not different in PRAD compared to normal tissues (f1). As for tumor types without normal tissue data in TCGA, we analyzed MMP1 expression by combining TCGA and GTEx data. We found higher expression of MMP1 in tumor tissues from DLBC, SKCM and UCS (f1).

Next, we obtained MMP1 protein levels by utilizing the CPTAC dataset from the National Cancer Institute. The data revealed that MMP1 protein levels in COAD, HNSC, LUAD and PAAD were significantly higher than in control tissues (f1). Moreover, GEPIA2 were utilized to investigate the correlation between MMP1 expression and pathological stages. MMP1 expression was significantly related to the tumor stage in 9 cancer types (f1). Taken together, these data showed that MMP1 expression was elevated in most tumor types from TCGA.

Diagnostic and prognostic roles of MMP1 in cancer patients

To understand the correlation between MMP1 expression and prognosis, we investigated the correlation between MMP1 high and low expression groups and prognosis using the TCGA dataset. High MMP1 expression was related to poor OS in 9 tumor types. However, in OV, high MMP1 expression may be related to better OS (f2). In addition, high MMP1 expression was related to poor DFS in 6 tumor types (f2).

We also used ROC curves to evaluate the diagnostic accuracy of MMP1 in human tumors. The data suggested that MMP1 had a high accuracy (AUC > 0.9) in predicting the diagnosis in 15 cancer types (f3).

The genetic alteration of MMP1 in TCGA tumor types

As we know, genetic alterations promote tumor development. To investigate the genetic alterations of MMP1, we utilized the cBioPortal website to analyze data from TCGA. We found that MMP1 gene alterations were most frequent (> 8%) in cervical squamous cell carcinoma among all tumors, and the predominant type of alterations was amplification (f4). As shown in f4, the most frequently mutated region (P412S/H/L) in MMP1 protein was mutated four times in total.

Moreover, we further investigated the relationship between MMP1 gene alterations and prognosis, and we presented meaningful results in f4. STAD patients with MMP1 gene alterations had poor DFS, DSS, OS, and PFS. In patients with BRCA, people with MMP1 gene alterations had a poor OS. However, with MMP1 gene alterations, OV patients had a better prognosis in DSS.

Immune infiltration analysis

Malignant solid tumor tissue includes many types of cells. In addition to tumor cells, stromal cells and infiltrating immune cells are also considered to play an important role in tumor progression. It is unclear whether the MMP1 expression influences the recruitment of immune cells. We used TIDE, EPIC and MCPCOUNTER algorithms to analyze the correlation between immune cells infiltration and MMP1 expression in pan-cancer based on the TIMER2. We found that CAFs was positively related to MMP1 expression in 31 tumor types, and CAFs was significantly related to MMP1 expression in 18 tumor types (f5).

We also analyzed immune cells and stromal cells to determine the stromal, immune, and estimate scores. Eventually, we found a significant correlation between MMP1 expression and stromal score in 24 tumor types, and all of them were positively correlated (Supplementary Figure 1). Moreover, MMP1 expression was positively and significantly related to immune score in 16 tumor types. However, THYM and TGCT were negatively related (Supplementary Figure 2). In the relationship between MMP1 expression and estimate score, MMP1 expression was significantly associated with estimate score in 22 tumor types. A negative correlation was found in THYM, and other tumor types were positively related to MMP1 expression (Supplementary Figure 3). Above all, MMP1 expression had a correlation with immune infiltration.

Relationship between MMP1 expression and TMB and MSI

We calculated the spearman correlation between MMP1 expression and TMB and MSI, and observed a positive correlation between MMP1 expression and TMB in ACC (r=0.30, p=2.0e-2), BRCA (r=0.29, p=1.35e-20), KICH (r=0.43, p=3.9e-4), SARC (r=0.18, p=6.8e-3), STAD (r=0.14, p=4.3e-3), THYM (r=0.29, p=1.5e-3) and UCS (r=0.33, p=1.3e-2). In contrast, MMP1 expression was significantly and negatively related to TMB in BLCA (r=-0.13, p=8.4e-3), GBM (r=-0.18, p=3.0e-2), HNSC (r=-0.14, p=1.3e-3) and KIRP (r=-0.14, p=2.8e-2) (f6). In COAD (r=0.21, p=3.6e-7), TGCT (r=0.22, p=7.4e-3) and UCEC (r=0.18, p=1.3e-2), MMP1 expression had a positive correlation with MSI, whereas in GBM (r=-0.12, p=3.5e-2), HNSC (r=-0.11, p=1.7e-2), LUAD (r=-0.12, p=2.0e-4), LUSC (r=-0.11, p=1.8e-2) and PAAD (r=-0.16, p=3.9e-2), it was adversely connected with MSI (f6).

Enrichment analysis of genes related to MMP1

We extracted the top 20 genes most closely related to MMP1 via GeneMANIA (f7). Subsequently, GO enrichment analysis showed that these 20 genes were mainly correlated with extracellular structure organization/extracellular matrix organization/extracellular matrix disassembly/collagen metabolic process in the enriched biological processes (BP), and the enriched cellular components (CC) were mainly associated with collagen−containing extracellular matrix, platelet alpha granule platelet alpha granule lumen and tertiary granule lumen. Besides, molecular functions (MF) were related to endopeptidase activity, metallopeptidase activity, serine−type endopeptidase activity and metalloendopeptidase activity (f7).

Moreover, we utilized the STRING tool to obtain 20 MMP1-interacting proteins and create a PPI network, which was showed in f7. These proteins were also enriched in extracellular structure organization/extracellular matrix organization/extracellular matrix disassembly, and the major enriched KEGG pathways were related to IL−17 signaling pathway, EGFR tyrosine kinase inhibitor resistance, and inflammatory bowel disease (f7).

The expression of MMP1 in PAAD cells and effect of MMP1 on migration, invasion, proliferation and apoptosis of PAAD cells

To validate the function of MMP1, we chose human pancreatic cancer for further investigation. Compared with HPDE, WB results suggested that MMP1 protein had a high expression in pancreatic cancer cells (f8). We also obtained the immunohistochemical pictures of MMP1 expression levels in pancreatic cancer from the HPA database (f8). Immunohistochemical results showed that MMP1 was overexpressed in pancreatic cancer. Then, we designed an siRNA against MMP1 and transfected it into Bxpc-3 and Capan-2 cells to examine the effect of MMP1 in PAAD cells. The results of WB demonstrated that siRNA had efficiency in inhibiting MMP1 expression (f8). Next, we found that silence of MMP1 could reduce the PAAD cells migration and invasion ability (f8). Subsequently, we examined the changes in cell viability after transfection in the normal cell group and the siMMP1-transfected group using the CCK8 kit. The results showed that the proliferation ability of PAAD cells was significantly reduced after 48 hours of MMP1 knockdown (f8). Meanwhile, we used flow cytometry to demonstrate that the knockdown of MMP1 also promoted PAAD cells apoptosis (f8). Therefore, these results indicated that MMP1 promoted the metastasis and inhibited the apoptosis of PAAD cells.

Discussion

In our study, we utilized different databases such as TCGA, GEO and HPA to comprehensively investigate the molecular characteristics of MMP1 in human tumors for the sake of investigating the value of MMP1 in clinic prognosis and immunotherapy.

Our findings revealed that MMP1 expression was higher in 22 tumor types and only lower in KICH than in paired normal tissues. In addition, UALCAN database was used to confirm that protein levels of MMP1 were higher in COAD, HNSC, PAAD, and LUAD tumor tissues than in corresponding controls. Moreover, high MMP1 expression was associated with advanced clinical stages in 8 tumor types. Several studies have proved that MMP1 may be related to poor prognosis in tumors such as BRCA, CESC and COAD (ref. 10, ref. 14, ref. 15). In our study, we performed KM survival analysis using multiple databases and found that in general, high MMP1 expression predicted poor OS and DFS outcomes. Only in OV, high MMP1 expression expressed a better OS outcome. However, A previous study came to the opposite conclusion (ref. 19). In this study published in 2017, the investigators found that high MMP1 mRNA expression was significantly associated with poor OS in OV using KMplot software. Recently, we used KMplot software to perform the analysis again, but did not draw conclusions consistent with this study, which is mainly due to the continuous update of database. So, this more reflects the importance of biological experiments for the verification of bioinformatics analysis. In addition, we employed ROC curves to explore the predictive accuracy of MMP1 in tumors. The results demonstrated that MMP1 had high predictive accuracy (AUC > 0.9) in 15 tumor types. Combined with survival analysis and ROC curve analysis, we concluded that MMP1 expression was related to the prognosis of OS or DFS in CESC, GBM, HNSC, OV, and PAAD, and had high diagnostic value. In LIHC, MMP1 expression was associated with OS and DFS outcomes, which is consistent with a previous study (ref. 20). However, ROC curves showed that MMP1 didn’t have a high predictive accuracy in LIHC, and thus the prognostic role of MMP1 in HCC remained of concern. Interestingly, we found that MMP1 expression was low in KICH, which is consistent with a prior study (ref. 21), but high expression of MMP1 was related to advanced clinical stage, and had poor prognosis. Therefore, we speculated that MMP1 may be involved in regulating a negative feedback regulatory mechanism in KICH. We also found no statistical differences in the protein levels of MMP1 from most tumor types, which should be related to the fact that protein expression is regulated at multiple levels.

It has been shown that genetic alterations have an important impact on the cancer prognosis (ref. 22, ref. 23). This research also showed that MMP1 had the highest mutation frequency in CESC, and the mutation frequency in HNSC was third in all tumor types, which was agreed with earlier studies reporting that genetic alterations in MMP1 were associated with HNSC (ref. 24). We further analyzed the effect of MMP1 mutation on the prognosis and survival of cancer patients. Although MMP1 expression had no effect on the prognosis of STAD, we found that MMP1 mutation had an effect on OS, DFS, DSS and PFS of STAD. No other researchers have yet investigated the role of MMP1 mutation in STAD.

Numerous studies have shown that the tumor microenvironment (TME) has an important influence on tumor development, in addition to being affected by the characteristics of tumor cells themselves. As an important component of TME, CAF also affects the development of tumors (ref. 25). On the one hand, CAFs can secrete a variety of cytokines to directly stimulate tumor cell proliferation and angiogenesis, and promote tumor growth, invasion and metastasis (ref. 26–ref. 28). On the other hand, they can remodel the extracellular matrix (ECM), form a permeability barrier of drugs, and prevent the effective penetration of anti-tumor drugs (ref. 29, ref. 30). In our study, we used TIDE, EPIC and MCPCOUNTER algorithm to analyze the relationship between CAFs and MMP1 expression on the TIMER2 website. We found that CAFs infiltration positively correlated with MMP1 expression in 31 tumor types, and after three algorithms validation, CAFs was significantly related to MMP1 expression in 18 tumor types.

It has been reported that MMP1 could improve tumor resistance by regulating CAFs in HNSC (ref. 31). In our study, we also came to a consistent conclusion that CAFs are significantly positively correlated with MMP1 expression in HNSC. Another study showed that CAFs could regulate apoptotic signaling pathways in tumor cells to promote tumor growth. CAFs have been found to be involved in mediating the clinical resistance of various malignancies such as STAD (ref. 32), LUAD (ref. 33), LIHC (ref. 34) and COAD (ref. 35). These studies revealed the potential for MMP1 to become a clinical target. It has also been suggested that MMP1 participated in the regulation of tumor-associated macrophages in colon cancer (ref. 36), but our study did not find a close relationship between MMP1 and tumor-associated macrophages in pan-cancer. Also, we analyzed immune cells and stromal cells to obtain stromal, immune, and estimate scores in each tumor. In addition, we calculated spearman’s correlation between MMP1 expression and tumor mutational burden and microsatellite instability in each cancer type (ref. 37). The results suggested that MMP1 was associated with tumor immunity.

It has been reported that CAFs are important cellular components involved in ECM remodeling, which help tumor growth by increasing the deposition of certain components of ECM to induce stromal changes (ref. 38, ref. 39). Through enrichment analysis of MMP1-related genes (ref. 40), we found that the main functions of MMP1 lay in extracellular structure/extracellular matrix organization/extracellular matrix disassembly/collagen metabolic process, which is consistent with prior studies. Combined with the phenomenon that MMP1 expression was closely associated with CAFs infiltration, we concluded that MMP1 not only acted to degrade extracellular matrix and promote tumor metastasis (ref. 41, ref. 42), but also promoted the production of extratumoral matrix by CAFs, thereby promoting tumor development (ref. 43, ref. 44).

In addition, we verified that MMP1 was highly expressed in PAAD cell lines using molecular biology experiments and was involved in migration, invasion, proliferation and apoptosis of PAAD cells. It was indicated that circular RNA circDLC1 could inhibit liver cancer development by interacting with MMP1 (ref. 45). Another study showed that MMP1 was involved in the cancer-promoting effect of TCONS_00012883 on colorectal cancer (ref. 46). These studies suggested that MMP1 may be able to be a prognostic and immune-related biomarker (ref. 47–ref. 49). However, although we explored the relationship of MMP1 expression with clinical outcome and tumor immune infiltration using several databases, this study still needs to go further to obtain more rigorous conclusions. We need more biological experiments to explore the specific mechanism of MMP1 in tumor progression (ref. 50). In addition, the specific effect of MMP1 on CAFs in different tumors needs further validations.

Overall, our study elucidated the correlation between MMP1 expression and clinical prognosis and immune infiltration. We also utilized biological experiments to validate the cancer-promoting effect of MMP1 in pancreatic cancer. It provides a theoretical basis for introducing MMP1 as a new prognostic and immunological biomarker.

Conclusion

Our study comprehensively proved that MMP1 expression is related to clinical prognosis and tumor immune infiltration, and MMP1 can become a prognostic and immunological biomarker.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Author contributionss

SM, AX, XT and GL contributed to the conception of the study. SM, DY, MS, HW and JQ contributed materials and performed the experiment. SM and XT performed the data analyses. SM, AX and GL contributed significantly in writing the manuscript. All authors contributed to the article and approved the submitted version.

References

1. C Xia, X Dong, H Li, M Cao, D Sun, S He. Cancer statistics in China and united states, 2022: Profiles, trends, and determinants.. Chin Med J (Engl) (, 2022. [DOI]
2. H Sung, J Ferlay, RL Siegel, M Laversanne, I Soerjomataram, A Jemal. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.. CA Cancer J Clin (, 2021. [DOI]
3. L Chin, JN Andersen, PA Futreal. Cancer genomics: From discovery science to personalized medicine.. Nat Med (, 2011. [DOI | PubMed]
4. A Blum, P Wang, JC Zenklusen. Snapshot: Tcga-analyzed tumors.. Cell (, 2018. [DOI | PubMed]
5. K Tomczak, P Czerwińska, M Wiznerowicz. The cancer genome atlas (Tcga): An immeasurable source of knowledge.. Contemp Oncol (Pozn) (, 2015. [DOI]
6. C Padala, MA Tupurani, K Puranam, S Gantala, N Shyamala, MS Kondapalli. Synergistic effect of collagenase-1 (Mmp1), stromelysin-1 (Mmp3) and gelatinase-b (Mmp9) gene polymorphisms in breast cancer.. PLos One (, 2017. [DOI | PubMed]
7. CS Benson, SD Babu, S Radhakrishna, N Selvamurugan, B Ravi Sankar. Expression of matrix metalloproteinases in human breast cancer tissues.. Dis Markers (, 2013. [DOI | PubMed]
8. H Liu, Y Kato, SA Erzinger, GM Kiriakova, Y Qian, D Palmieri. The role of mmp-1 in breast cancer growth and metastasis to the brain in a xenograft model.. BMC Cancer (, 2012. [DOI | PubMed]
9. YX Li, XX Zhu, X Wu, JH Li, XH Ni, SJ Li. Aclp promotes activation of cancer-associated fibroblasts and tumor metastasis Via aclp-Pparγ-Aclp feedback loop in pancreatic cancer.. Cancer Lett (, 2022. [DOI | PubMed]
10. X Lu, Q Wang, G Hu, C Van Poznak, M Fleisher, M Reiss. Adamts1 and Mmp1 proteolytically engage egf-like ligands in an osteolytic signaling cascade for bone metastasis.. Genes Dev (, 2009. [DOI]
11. A Juncker-Jensen, EI Deryugina, I Rimann, E Zajac, TA Kupriyanova, LH Engelholm. Tumor mmp-1 activates endothelial Par1 to facilitate vascular intravasation and metastatic dissemination.. Cancer Res (, 2013. [DOI]
12. KB Hotary, ED Allen, PC Brooks, NS Datta, MW Long, SJ Weiss. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix.. Cell (, 2003. [DOI | PubMed]
13. LJ McCawley, LM Matrisian. Matrix metalloproteinases: They’re not just for matrix anymore!. Curr Opin Cell Biol (, 2001. [DOI]
14. S Zhao, M Yu. Identification of Mmp1 as a potential prognostic biomarker and correlating with immune infiltrates in cervical squamous cell carcinoma.. DNA Cell Biol (, 2020. [DOI]
15. A Jonsson, P Falk, E Angenete, C Hjalmarsson, ML Ivarsson. Plasma mmp-1 expression as a prognostic factor in colon cancer.. J Surg Res (, 2021. [DOI]
16. L Yang, W Rong, T Xiao, Y Zhang, B Xu, Y Liu. Secretory/Releasing proteome-based identification of plasma biomarkers in hbv-associated hepatocellular carcinoma.. Sci China Life Sci (, 2013. [DOI]
17. J Vivian, AA Rao, FA Nothaft, C Ketchum, J Armstrong, A Novak. Toil enables reproducible, open source, big biomedical data analyses.. Nat Biotechnol (, 2017. [DOI]
18. R Bonneville, MA Krook, EA Kautto, J Miya, MR Wing, HZ Chen. Landscape of microsatellite instability across 39 cancer types.. JCO Precis Oncol (, 2017. [DOI]
19. A Yokoi, Y Yoshioka, Y Yamamoto, M Ishikawa, SI Ikeda, T Kato. Malignant extracellular vesicles carrying Mmp1 mrna facilitate peritoneal dissemination in ovarian cancer.. Nat Commun (, 2017. [DOI | PubMed]
20. L Dai, J Mugaanyi, X Cai, M Dong, C Lu, C Lu. Comprehensive bioinformatic analysis of Mmp1 in hepatocellular carcinoma and establishment of relevant prognostic model.. Sci Rep (, 2022. [DOI | PubMed]
21. G Młynarczyk, J Kudelski, B Darewicz, M Bruczko-Goralewska, L Romanowicz. Suppressed expression but not activity of collagenases mmp-1 and mmp-13 in human renal carcinoma.. Pathobiology (, 2019. [DOI]
22. Z Zhou, X Ma, F Wang, L Sun, G Zhang. A matrix metalloproteinase-1 polymorphism, Mmp1-1607 (1g>2g), is associated with increased cancer risk: A meta-analysis including 21,327 patients.. Dis Markers (, 2018. [DOI | PubMed]
23. C Luan, Y Xu. Matrix metalloproteinase gene mutations and bioinformatics of telocytes in hepatocellular carcinoma.. Cell Biol Int (, 2022. [DOI]
24. J Aparna, AS Smiline-Girija, A Paramasivam, J Vijayashree-Priyadharsini. Deciphering the genetic alterations in matrix metallo-proteinase gene family and its putative association with head and neck squamous cell carcinoma.. Mol Biol Res Commun (, 2021. [DOI | PubMed]
25. E Sahai, I Astsaturov, E Cukierman, DG DeNardo, M Egeblad, RM Evans. A framework for advancing our understanding of cancer-associated fibroblasts.. Nat Rev Cancer (, 2020. [DOI]
26. D Goehrig, J Nigri, R Samain, Z Wu, P Cappello, G Gabiane. Stromal protein Βig-H3 reprogrammes tumour microenvironment in pancreatic cancer.. Gut (, 2019. [DOI | PubMed]
27. D Unterleuthner, P Neuhold, K Schwarz, L Janker, B Neuditschko, H Nivarthi. Cancer-associated fibroblast-derived Wnt2 increases tumor angiogenesis in colon cancer.. Angiogenesis (, 2020. [DOI]
28. X Li, Q Song, X Guo, L Wang, Q Zhang, L Cao. The metastasis potential promoting capacity of cancer-associated fibroblasts was attenuated by cisplatin Via modulating Krt8.. Onco Targets Ther (, 2020. [DOI]
29. KR Levental, H Yu, L Kass, JN Lakins, M Egeblad, JT Erler. Matrix crosslinking forces tumor progression by enhancing integrin signaling.. Cell (, 2009. [DOI | PubMed]
30. T Uchihara, K Miyake, A Yonemura, Y Komohara, R Itoyama, M Koiwa. Extracellular vesicles from cancer-associated fibroblasts containing annexin A6 induces fak-yap activation by stabilizing Β1 integrin, enhancing drug resistance.. Cancer Res (, 2020. [DOI]
31. AC Johansson, A Ansell, F Jerhammar, MB Lindh, R Grénman, E Munck-Wikland. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells.. Mol Cancer Res (, 2012. [DOI]
32. H Zhang, T Deng, R Liu, T Ning, H Yang, D Liu. Caf secreted mir-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer.. Mol Cancer (, 2020. [DOI | PubMed]
33. L Wang, X Li, Y Ren, H Geng, Q Zhang, L Cao. Cancer-associated fibroblasts contribute to cisplatin resistance by modulating Anxa3 in lung cancer cells.. Cancer Sci (, 2019. [DOI]
34. J Liu, P Li, L Wang, M Li, Z Ge, L Noordam. Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance.. Cell Mol Gastroenterol Hepatol (, 2021. [DOI]
35. J Ren, L Ding, D Zhang, G Shi, Q Xu, S Shen. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncrna H19.. Theranostics (, 2018. [DOI]
36. J Yu, Z Xu, J Guo, K Yang, J Zheng, X Sun. Tumor-associated macrophages (Tams) depend on Mmp1 for their cancer-promoting role.. Cell Death Discovery (, 2021. [DOI | PubMed]
37. A Rizzo, AD Ricci, G Brandi. Pd-L1, tmb, msi, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer.. Cancers (Basel) (, 2021. [DOI | PubMed]
38. A Noël, A Gutiérrez-Fernández, NE Sounni, N Behrendt, E Maquoi, IK Lund. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment.. Front Pharmacol (, 2012. [DOI | PubMed]
39. A Jabłońska-Trypuć, M Matejczyk, S Rosochacki. Matrix metalloproteinases (Mmps), the main extracellular matrix (Ecm) enzymes in collagen degradation, as a target for anticancer drugs.. J Enzyme Inhib Med Chem (, 2016. [DOI]
40. The gene ontology resource: 20 years and still going strong.. Nucleic Acids Res (, 2019. [DOI]
41. D Pei. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface.. Cancer Cell (, 2005. [DOI]
42. CC Lynch, LM Matrisian. Matrix metalloproteinases in tumor-host cell communication.. Differentiation (, 2002. [DOI]
43. PY Chen, WF Wei, HZ Wu, LS Fan, W Wang. Cancer-associated fibroblast heterogeneity: A factor that cannot be ignored in immune microenvironment remodeling.. Front Immunol (, 2021. [DOI | PubMed]
44. SN Kim, A Jeibmann, K Halama, HT Witte, M Wälte, T Matzat. Ecm stiffness regulates glial migration in drosophila and mammalian glioma models.. Development (, 2014. [DOI]
45. H Liu, T Lan, H Li, L Xu, X Chen, H Liao. Circular rna Circdlc1 inhibits Mmp1-mediated liver cancer progression Via interaction with hur.. Theranostics (, 2021. [DOI]
46. P Yang, J Li, C Peng, Y Tan, R Chen, W Peng. Tcons_00012883 promotes proliferation and metastasis Via Ddx3/Yy1/Mmp1/Pi3k-akt axis in colorectal cancer.. Clin Transl Med (, 2020. [DOI | PubMed]
47. M Liu, Y Hu, MF Zhang, KJ Luo, XY Xie, J Wen. Mmp1 promotes tumor growth and metastasis in esophageal squamous cell carcinoma.. Cancer Lett (, 2016. [DOI | PubMed]
48. CY Lin, A Chao, TH Wang, S Hsueh, YS Lee, TI Wu. A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (Mmp1) in endometrial cancer.. J Mol Med (Berl) (, 2014. [DOI]
49. IO Rosas, TJ Richards, K Konishi, Y Zhang, K Gibson, AE Lokshin. Mmp1 and Mmp7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis.. PLos Med (, 2008. [DOI | PubMed]
50. A Xia, W Yuan, Q Wang, J Xu, Y Gu, L Zhang. The cancer-testis lncrna lnc-cthcc promotes hepatocellular carcinogenesis by binding hnrnp K and activating Yap1 transcription.. Nat Cancer (, 2022. [DOI]